This study, called LIFT, is looking at how two medications, Pyridostigmine and Low-Dose Naltrexone (LDN), might help people with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) and Long COVID. You might be able to join if you are between 18 and 70 years old and have ME/CFS or Long COVID with orthostatic intolerance (OI), meaning your symptoms worsen when you stand up. The study aims to see if these medications can improve your functional capacity (how well you can do daily activities) and how your body uses oxygen. There are 160 participants planned for this study, which is being conducted at Brigham and Women's Hospital.

Study design

This is a double-blind, placebo-controlled study, meaning neither you nor your doctors will know if you are receiving the active drugs or a placebo (an inactive substance). You would be randomly assigned to one of four groups: Pyridostigmine and LDN, Pyridostigmine and placebo, LDN and placebo, or two placebos.

What's involved

You would take Pyridostigmine and/or LDN (or placebos) with doses gradually increasing over 13 weeks. Your functional capacity will be measured at 15 weeks, and your body's oxygen use will be measured at 13 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary measurements for the study are taken at 13 and 15 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.